NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose.

Trial Profile

NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs NGR-TNF (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 May 2008 The actual number of patients enrolled was 16.
    • 05 May 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 06 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top